

ABSTRACT OF THE DISCLOSURE

1
2 An analgesic/anti-inflammatory pharmaceutical dosage
3 form which comprises an effective amount of an active
4 ingredient selected from the group consisting of racemic 5-
5 benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically
6 active forms thereof and pharmaceutically acceptable salts
7 thereof, in combination with a pharmaceutically acceptable
8 excipient or diluent, said dosage form being an intranasally
9 administrable dosage form.